Oral News and Research

RSS

Benefit of exenatide has not yet been proven

Since May 2007, a new drug has been available for the treatment of patients with diabetes mellitus type 2 in Germany: exenatide (trade name: Byetta), which is marketed by the manufacturer Eli Lilly.

18 Oct 2007

Oral antibiotics effective to treat severe urinary tract infections

Although doctors routinely use IV antibiotics to cure patients with severe urinary tract infections (UTI), a new review from suggests that oral antibiotics work just as well - from treating acute symptoms to preventing long-term complications of UTI.

17 Oct 2007

Chinese medicine for menstrual cramps

Women with menstrual cramps are often offered either non steroidal anti-inflammatory drugs or oral contraceptives.

17 Oct 2007

Older men with HIV often have sex without condoms

As many as four out of ten HIV positive African-American men could be putting their partners at risk by not using condoms, according to research in the latest UK-based Journal of Advanced Nursing.

16 Oct 2007

Pain medication use does not impair driving skills and reaction times according to new study

Moderate, long-term pain medication use does not impair a person's ability to drive safely, according to a new study.

15 Oct 2007

18F-DG PET/CT can highly increase the detection of colorectal cancer

Combined positron emission tomography and computed tomography (PET/CT) is currently widely used in the clinical diagnosis of cancer to provide functional and morphological imaging.

10 Oct 2007

Tooth loss may predict the development of dementia

Tooth loss may predict the development of dementia late in life, according to a study by University of Kentucky researchers.

10 Oct 2007

$Accentia announces investigational new drug application for Revimmune for refractory MS$

Accentia announces investigational new drug application for Revimmune for refractory MS

Accentia Biopharmaceuticals has announced that it met with the Food and Drug Administration (FDA) on September 26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune.

10 Oct 2007

Xeloda (capecitabine) better all round for cancer patients

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

9 Oct 2007

Potential new treatment for Huntington's disease found

MassGeneral Institute for Neurodegererative Disorders (MIND) researchers have identified a compound that may lead to a treatment that could protect against the effects of Huntington's Disease (HD).

9 Oct 2007

New report says 'treat smokers like drug addicts'

According to the the Royal College of Physicians (RCP), heavily-addicted smokers in Britain who find it impossible to quit are being let down.

7 Oct 2007

Good dental care, not antibiotics best for preventing dental-related heart problems

Since the 1950s, the American Heart Association (AHA) has urged a sizable group of people to take antibiotics before having dental work or other procedures that might flood the bloodstream with bacteria.

4 Oct 2007

Improvements in cancer survival in Northern Ireland

There have been improvements in cancer survival in Northern Ireland between 1993 and 2004, according to a new report from the Northern Ireland Cancer Registry (NICR), launched at Queen’s today.

4 Oct 2007

Specific immune deficiency pinpointed as likely cause of ulcerative colitis

In a series of mouse experiments, researchers at the Harvard School of Public Health (HSPH) have pinpointed a specific immune deficiency as the likely fundamental cause of ulcerative colitis, a chronic, sometimes severe inflammatory disease of the colon or large intestine that afflicts half a million Americans.

4 Oct 2007

$4 million nursing grant for premature infants

The University of Illinois at Chicago College of Nursing has received a $4.1 million federal grant to develop ways to improve the early growth and development of premature infants who have two or more social-environmental risks such as poverty or minority status.

4 Oct 2007

Large gap between physician and patient understanding of necessity of monthly periods

More than the two thirds of the women in a national survey say that they are interested in suppressing their menstrual periods but many of them aren't sure if it's safe.

4 Oct 2007

Cancer drug Taxotere given the green light to treat head and neck cancer

Following promising results in a phase III trial, the drug Taxotere has been given the green light for use in people with head and neck cancer.

2 Oct 2007

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

2 Oct 2007

Antibiotic Minocycline shows potential as stroke treatment

People treated with the drug minocycline within six to 24 hours after a stroke had significantly fewer disabilities, according to a study published in the October 2, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Oct 2007

Oncolytics Biotech reports positive interim results of UK phase Ia/Ib trials

Oncolytics Biotech Inc. has announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K.

29 Sep 2007